Table 1.
Characteristics of patients.
Table 2.
Thiopurine metabolites levels in different subgroups.
Table 3.
Association 6-TGN levels and clinical response (multivariable logistic regression analyses).
Fig 1.
The frequency of patients with therapeutic non-response according to 6-TGN concentrations.
Fig 2.
WBC count as a percentage of baseline at 4 weeks after thiopurines treatment; (A) NUDT15 genotype, (B) TPMT genotype.
CDAI, Crohn’s disease activity index; CRP, C-reactive protein; 6-TGN, 6-thioguanine nucleotides.
Table 4.
The risk of leukopenia according to NUDT15 and TPMT genotype.